Company: IMRX
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0001790340-25-000042
Chunk: 3

Company: Immuneering Corp
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 3
---
3,606,996 Other income, net441,493 1,334,269 Net loss$(61,036,608)$(53,471,622)Net loss per share attributable to common stockholders, basic and diluted(2.04)(1.88)Weighted-average common shares outstanding, basic and diluted29,981,56528,416,558Other comprehensive income:Unrealized gain from marketable securities778 29,342 Comprehensive Loss$(61,035,830)$(53,442,280)

The accompanying notes are an integral part of these consolidated financial statements.

121

IMMUNEERING CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023

Class A Common StockClass B Common StockAdditionalPaid-In CapitalAccumulated Other Comprehensive Income (Loss)AccumulatedDeficitTotalStockholders' EquitySharesPar ValueSharesPar Value Balance at December 31, 202226,418,732$26,419 —$— $219,640,912 $(30,120)$(109,786,956)$109,850,255 Issuance of common stock upon exercise of stock options125,624126 —— 444,712 — — 444,838 Issuance of common stock upon public offering, net of commissions, underwriting discounts and $203,768 in issuance costs2,727,2732,727 —— 27,993,508 — — 27,996,235 Stock-based compensation expense—— —— 5,727,135 — — 5,727,135 Net loss—— —— — — (53,471,622)(53,471,622)Other comprehensive income—— —— — 29,342 — 29,342 Balance at December 31, 202329,271,629$29,272 —$— $253,806,267 $(778)$(163,258,578)$90,576,183 Issuance of common stock upon exercise of stock options229,299 229 —— 732,229 — — 732,458 Issuance of common stock under at-the-market offering, net of commissions, underwriting discounts and $86,374 issuance costs1,318,7521,319